4 completed, 4 terminated, 3 recruiting, 3 withdrawn. 10 Phase 2, 6 Phase 1, 1 Early Phase 1, 1 Phase 3.
Follow Recurrent Endometrial Cancer: new trials by email Literature Review of Recurrent Endometrial Cancer trials Research Report on Recurrent Endometrial Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Assessing Survival Outcomes With Checkpoint Inhibition ExteNded vs Discontinued in Endometrial Cancer anti-PD1 agent therapy - 1 year, anti-PD1 agent therapy - 2 years - Endometrial Adenocarcinoma, Metastatic Endometrial Cancer | Phase 3 | Not yet recruiting | UNC Lineberger Comprehensive Cancer Center | 140 | 2026-10-01 | 2026-10-15 |
| Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Progression on or Following First-Line Immunotherapy Maintenance Pembrolizumab, Lenvatinib - Recurrent Endometrial Cancer | Phase 2 | Recruiting | University of Miami | 46 | 2026-08-06 | 2026-09-24 |
| ALPINE: Maintenance Letrozole/Abemaciclib Abemaciclib, Letrozole, Pembrolizumab - Endometrial Cancer, Recurrent Endometrial Cancer | Phase 2 | Recruiting | Dana-Farber Cancer Institute | 32 | 2024-09-25 | 2026-10-15 |
| Study of ART0380 in Patients With Biologically Selected Solid Tumors ART0380 - Advanced Solid Tumor, Recurrent Endometrial Cancer | Phase 2 | Terminated | Artios Pharma Ltd | 36 | 2023-09-06 | 2025-11-06 |
| Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System pembrolizumab, Sitravatinib - Recurrent Endometrial Cancer, Solid Tumors | Phase 2 | Withdrawn | Haider Mahdi | 2022-09-08 | 2023-02-27 | |
| Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer Lenvatinib, Pembrolizumab - Endometrial Cancer, Mismatch Repair-Proficient | Phase 2 | Terminated | Virginia Commonwealth University | 4 | 2022-04-01 | 2025-10-02 |
| Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer Biopsy, Carboplatin, Paclitaxel - Lynch Syndrome, Recurrent Endometrial Carcinoma | Early Phase 1 | Terminated | Floor Backes, MD | 2 | 2021-07-01 | 2025-02-13 |
| Pembrolizumab With Axitinib in Recurrent Endometrial Cancer Pembrolizumab, Axitinib - Recurrent Endometrial Cancer | Phase 2 | Withdrawn | Case Comprehensive Cancer Center | 2021-02-01 | 2020-11-05 | |
| Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer Durvalumab, Tremelimumab, Radiation Therapy - Recurrent Gynecological Cancer, Metastatic Cervical Cancer | Phase 1 | Terminated | Dana-Farber Cancer Institute | 16 | 2018-06-01 | 2025-05-31 |
| Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers Ubamatamab, Cemiplimab, Sarilumab - Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer | Phase 1 / Phase 2 | Recruiting | Regeneron Pharmaceuticals | 890 | 2018-05-21 | 2026-09-25 |
| Safety and Efficacy of Metronomic Cyclophosphamide, Metformin and Olaparib in Endometrial Cancer Patients Olaparib, metformin, metronomic cyclophosphamide - Recurrent Endometrial Cancer | Phase 1 / Phase 2 | Completed | Hospices Civils de Lyon | 35 | 2016-09-23 | 2026-05-27 |
| Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer Pembrolizumab - Recurrent Endometrial Cancer | Phase 2 | Completed | Yale University | 25 | 2016-09-01 | 2025-06-11 |
| Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer Lenvatinib Mesylate, Paclitaxel, Pharmacological Study - Fallopian Tube Carcinoma, Recurrent Ovarian Cancer | Phase 1 | Completed | Floor Backes | 26 | 2016-05-27 | 2022-09-19 |
| Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer LY3023414 - Endometrial Cancer, Recurrent Endometrial Cancer | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 28 | 2015-09-01 | 2023-02-22 |
| Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian Cancer BKM120, Nabpaclitaxel - Ovarian Cancer, Endometrial Cancer | Phase 1 | Withdrawn | Rutgers, The State University of New Jersey | 2015-02-01 | 2022-07-28 | |
| A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or Carcinosarcoma Lapatinib and ixempra - Recurrent Endometrial Cancer | Phase 1 | Unknown | Hung-Hsueh Chou | 24 | 2011-03-01 | 2011-10-19 |
Endometrial Neoplasms (16) · Ovarian Neoplasms (4) · Fallopian Tube Neoplasms (2) · Colorectal Neoplasms, Hereditary Nonpolyposis (1) · Neoplasm Metastasis (1) · Recurrence (1) · Turcot syndrome (1) · Uterine Cervical Neoplasms (1) · Vaginal Neoplasms (1) · Vulvar Neoplasms (1)
Female Urogenital Diseases (16) · Female Urogenital Diseases and Pregnancy Complications (16) · Genital Diseases (16) · Genital Diseases, Female (16) · Genital Neoplasms, Female (16) · Neoplasms (16) · Neoplasms by Site (16) · Urogenital Diseases (16) · Urogenital Neoplasms (16) · Uterine Diseases (16) · Uterine Neoplasms (16) · Adnexal Diseases (4) · Endocrine Gland Neoplasms (4) · Endocrine System Diseases (4) · Gonadal Disorders (4)
pembrolizumab (6) · lenvatinib (3) · Paclitaxel (2) · Taxes (2) · Albumin-Bound Paclitaxel (1) · Antibodies, Monoclonal (1) · Axitinib (1) · Biopsy (1) · Biosimilar Pharmaceuticals (1) · Carboplatin (1) · Immunoglobulin G (1) · LY3023414 (1) · Lapatinib (1) · Letrozole (1) · Metformin (1)
Dana-Farber Cancer Institute (2) · Artios Pharma Ltd (1) · Case Comprehensive Cancer Center (1) · Floor Backes (1) · Floor Backes, MD (1) · Haider Mahdi (1) · Hospices Civils de Lyon (1) · Hung-Hsueh Chou (1) · Memorial Sloan Kettering Cancer Center (1) · Regeneron Pharmaceuticals (1) · Rutgers, The State University of New Jersey (1) · UNC Lineberger Comprehensive Cancer Center (1) · University of Miami (1) · Virginia Commonwealth University (1) · Yale University (1)
United States (11) · France (3) · Spain (2) · Australia (1) · Belgium (1) · Israel (1) · Italy (1) · Netherlands (1) · South Korea (1) · United Kingdom (1)
Floor Backes, MD (2) · Haider Mahdi, MD (2) · Alessandro D. Santin, M.D (1) · Chelsea Salyer, MD (1) · Darlene Gibbon, MD (1) · Martin King, MD, PhD (1) · Navya Nair, MD, MPH (1) · Olivia D Lara, MD, MS (1) · Panagiotis Konstantinopoulos, MD, PhD (1) · Vicky Makker, MD (1)
PMID 33932502, PMID 34875107, PMID 39652449, PMID 39979249, PMID 40273550, PMID 40334308
2015 (1), 2019 (1), 2023 (1)